Department of Cardiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Heart Vessels. 2021 Sep;36(9):1283-1289. doi: 10.1007/s00380-021-01817-y. Epub 2021 Mar 1.
While mortality of acute coronary syndrome (ACS) is known to have steadily decline over the last decades, data are lacking regarding the complex sub-population of patients with both coronary artery disease and cancer. A large single-center percutaneous coronary intervention (PCI) registry was used to retrieve patients who had a known diagnosis of malignancy during PCI. Patients were divided into two groups according to the period in which PCI was performed (period 1: 2006-2011, period 2: 2012-2017). Cox regression hazard models were implemented to compare primary endpoint, defined as the composite outcomes of major adverse cardiac events (MACE) (which include cardiovascular death, myocardial infarction or target vessel revascularization) and secondary endpoint of all-cause mortality, between the two time periods. A total of 3286 patients were included, 1819 (55%) had undergone PCI in period 1, and 1467 (45%) in period 2. Both short- and long-term MACE and overall mortality were significantly lower in patients who underwent PCI at the latter period (2.3% vs. 4.3%, p < 0.001 and 1.1% vs. 3.2%, p < 0.001 after 30 days and 24% vs. 30%, p < 0.001 and 12% vs. 22%, p < 0.001 after 2 years, respectively). However, in a multivariate analysis, going through PCI in the latter period was still associated with lower rates of overall mortality (HR 0.708, 95% confidence interval [CI] 0.53-0.93, p = 0.014) but there was no significant difference in MACE (HR 0.83, 95% CI 0.75-1.42, p = 0.16). Patients with cancer undergoing PCI during our most contemporary period had an improved overall survival, but no significant differences were observed in the composite cardiovascular endpoints, compared to an earlier PCI period. The management of coronary patients with cancer disease remains challenging.
虽然急性冠状动脉综合征(ACS)的死亡率在过去几十年中稳步下降,但关于同时患有冠状动脉疾病和癌症的复杂亚人群的数据仍然缺乏。一项大型单中心经皮冠状动脉介入治疗(PCI)登记研究用于检索在 PCI 期间已知患有恶性肿瘤的患者。根据 PCI 进行的时间段将患者分为两组(时间段 1:2006-2011 年,时间段 2:2012-2017 年)。实施 Cox 回归风险模型比较主要终点,定义为主要不良心脏事件(MACE)(包括心血管死亡、心肌梗死或靶血管血运重建)的复合结果和全因死亡率的次要终点,比较两个时间段之间的差异。共纳入 3286 例患者,1819 例(55%)在时间段 1 接受 PCI,1467 例(45%)在时间段 2 接受 PCI。与时间段 1 相比,在时间段 2 接受 PCI 的患者的短期和长期 MACE 和总死亡率均显著降低(30 天后分别为 2.3%比 4.3%,p<0.001 和 1.1%比 3.2%,p<0.001,2 年后分别为 24%比 30%,p<0.001 和 12%比 22%,p<0.001)。然而,在多变量分析中,在后期进行 PCI 仍然与较低的总死亡率相关(HR 0.708,95%置信区间[CI]0.53-0.93,p=0.014),但在 MACE 方面没有显著差异(HR 0.83,95%CI 0.75-1.42,p=0.16)。与早期 PCI 时期相比,在我们最近的时期接受 PCI 的癌症患者的整体生存率得到改善,但复合心血管终点没有显著差异。对患有癌症疾病的冠状动脉患者的管理仍然具有挑战性。